Clinical Research Directory

Inclusion Criteria: * Able to understand the key components of the study as described in the written informed consent document and willing and able to provide written informed consent. * At least 18 years of age at the time of screening. * Enrollment begins 30 days prior to transplant till day 29 post-transplantation. * Recipient of a kidney transplant (either primary or repeat), from either deceased or living donor. * Receiving any immunosuppressive regimen. * Able and willing to comply with all study procedures, as assessed by the Investigator. * Selected by the treating provider to undergo TruGraf and TRAC™ testing as part of routine post-transplant care Exclusion Criteria: History of previous non-kidney solid organ, vascular composite allograft, pancreatic islet, stem cell, or bone marrow transplant. * History of dual or en-bloc kidney transplants. * Recipient or donor with positive test for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B virus (HBV) nucleic acid testing (NAT), hepatitis C virus (HCV) antibody, HCV NAT, human immunodeficiency virus (HIV), or HIV NAT. * Patients known to be pregnant or with plans to become pregnant over the 24 months after enrollment. * History or presence of coagulopathy, thrombophilia, unexplained bleeding or clotting disorders, or use of or documented plans for use of systemic anticoagulants at the time of screening, with the exception of uremic coagulopathy or prophylactic heparin preparations. * History or presence, upon clinical evaluation, of any illness or condition that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions